Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by Bobbak Mansouri
Based on 13 articles published since 2010
(Why 13 articles?)
||||

Between 2010 and 2020, B. Mansouri wrote the following 13 articles about Psoriasis.
 
+ Citations + Abstracts
1 Review Pustular psoriasis: pathophysiology and current treatment perspectives. 2016

Benjegerdes, Katie E / Hyde, Kimberly / Kivelevitch, Dario / Mansouri, Bobbak. ·Texas A&M Health Science Center College of Medicine, Temple. · Texas A&M Health Science Center College of Medicine, Round Rock. · Division of Dermatology, Baylor University Medical Center, Dallas. · Department of Dermatology, Scott and White Hospital, Texas A&M Health Science Center College of Medicine, Temple, TX, USA. ·Psoriasis (Auckl) · Pubmed #29387600.

ABSTRACT: Psoriasis vulgaris is a chronic inflammatory disease that classically affects skin and joints and is associated with numerous comorbidities. There are several clinical subtypes of psoriasis including the uncommon pustular variants, which are subdivided into generalized and localized forms. Generalized forms of pustular psoriasis include acute generalized pustular psoriasis, pustular psoriasis of pregnancy, and infantile and juvenile pustular psoriasis. Localized forms include acrodermatitis continua of Hallopeau and palmoplantar pustular psoriasis. These subtypes vary in their presentations, but all have similar histopathologic characteristics. The immunopathogenesis of each entity remains to be fully elucidated and some debate exists as to whether these inflammatory pustular dermatoses should be classified as entities distinct from psoriasis vulgaris. Due to the rarity of these conditions and the questionable link to the common, plaque-type psoriasis, numerous therapies have shown variable results and most entities remain difficult to treat. With increasing knowledge of the pathogenesis of these variants of pustular psoriasis, the development and use of biologic and other immunomodulatory therapies holds promise for the future of successfully treating pustular variants of psoriasis.

2 Review A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. 2016

Campa, Molly / Mansouri, Bobbak / Warren, Richard / Menter, Alan. ·Division of Dermatology, Baylor University Medical Center, Dallas, TX, USA. · Department of Dermatology, Baylor Scott and White Medical Center, Temple, TX, USA. · University of Manchester, Manchester, UK. · Division of Dermatology, Baylor University Medical Center, Dallas, TX, USA. amderm@gmail.com. ·Dermatol Ther (Heidelb) · Pubmed #26714681.

ABSTRACT: The development of several highly effective biologic drugs in the past decade has revolutionized the treatment of moderate-to-severe plaque psoriasis. With increased understanding of the immunopathogenesis of psoriasis, the emphasis has turned toward more specific targets for psoriasis drugs. Although the complex immunological pathway of psoriasis is not yet completely understood, current models emphasize the significant importance of interleukin (IL)-23 and IL-17. Several biologic drugs targeting these cytokines are now in various stages of drug development. Drugs targeting IL-23 include BI-655066, briakinumab, guselkumab, tildrakizumab, and ustekinumab. Drugs targeting IL-17 include brodalumab, ixekizumab, and secukinumab. While many of these have shown safety and good efficacy in clinical trials of moderate-to-severe plaque psoriasis, long-term safety is still to be established.

3 Review Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. 2014

Kivelevitch, Dario / Mansouri, Bobbak / Menter, Alan. ·Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA. ·Biologics · Pubmed #24790410.

ABSTRACT: Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis.

4 Review Biological therapies for psoriasis. 2013

Mansouri, Bobbak / Patel, Mahir / Menter, Alan. ·Dermatology Research FellowBaylor University Medical Center, Division of Dermatology , 3900 Junius Street, Suite 125, Dallas, TX 75204 , USA. ·Expert Opin Biol Ther · Pubmed #24160990.

ABSTRACT: INTRODUCTION: Biological therapies have revolutionized moderate-to-severe psoriasis treatment. Increased understanding of disease pathogenesis has yielded multiple therapeutic targets involving the IL-23/Th17 pathway, while current therapies continue to be monitored for long-term efficacy and safety. AREAS COVERED: This review details current understanding of psoriasis immunopathogenesis specifically related to therapeutic targets. Approved and emerging biological psoriasis therapies targeting TNF-α, IL-12/23p40, IL-17 and IL-23p19 are covered. Biological agent uses in special circumstances are reviewed together with the emerging debate on biosimilar therapies and their potential future role in psoriasis and other inflammatory diseases. EXPERT OPINION: Psoriasis treatment has expanded and has become more effective due to increased understanding of disease pathogenesis. However, lack of efficacy in select psoriasis patients, safety concerns and limited treatment efficacy in psoriasis variants (e.g., pustular) are areas which still need improvement. As such, pharmacogenomics will be of vital importance in future for individualized psoriasis care. Further, a better understanding of the multiple psoriasis comorbidities, especially cardiovascular disease, continues to be of significant interest in the psoriasis community. Last, the emergence of biosimilar agents has the potential to change psoriasis treatment, especially as it relates to better access for the psoriasis community worldwide.

5 Review Tumour necrosis factor-α inhibitor use in patients with psoriasis with organ transplantation. 2013

Mansouri, B / Patel, M / Menter, A. · ·Br J Dermatol · Pubmed #23517414.

ABSTRACT: -- No abstract --

6 Article A narrative review of psoriasis and multiple sclerosis: links and risks. 2019

Silfvast-Kaiser, Annika S / Homan, Katie B / Mansouri, Bobbak. ·Department of Dermatology, Baylor Scott and White, Dallas, TX, USA. · Department of Dermatology, Baylor Scott and White Medical Center, Temple, TX, USA. · Austin Institute for Clinical Research, Pflugerville, TX, USA. · Sanova Dermatology - Pflugerville, Pflugerville, TX, USA. · U.S. Dermatology Partners - Tyler, TX, USA. ·Psoriasis (Auckl) · Pubmed #31687363.

ABSTRACT: The association of psoriasis (PsO) with other autoimmune and autoinflammatory diseases has long been a topic of interest. Although previous studies have attempted to clarify the specific relationship between PsO and multiple sclerosis (MS), it remains obscure, with limited and conflicting evidence regarding a link between the two entities. Herein, we review the etiology, pathogenesis, and treatment of each disease and present the available literature to-date regarding a possible relationship between PsO and MS. We conclude that further study is necessary to discern whether there may be a significant relationship between PsO and MS. In the meantime, clinicians may find it appropriate to screen for MS in patients with PsO, allowing for timely referral to a neurologist should it be necessary.

7 Article Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes. 2016

Mansouri, Bobbak / Kivelevitch, Dario / Natarajan, Balaji / Joshi, Aditya A / Ryan, Caitriona / Benjegerdes, Katie / Schussler, Jeffrey M / Rader, Daniel J / Reilly, Muredach P / Menter, Alan / Mehta, Nehal N. ·Division of Dermatology, Baylor University Medical Center, Dallas, Texas2Department of Dermatology, Baylor Scott and White Health, Temple, Texas. · Division of Dermatology, Baylor University Medical Center, Dallas, Texas3Baylor Institute for Immunology Research, Dallas, Texas. · University of Arizona College of Medicine at South Campus, Tucson5National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. · National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. · Division of Dermatology, Baylor University Medical Center, Dallas, Texas. · Texas A&M Health Science Center College of Medicine, Temple. · Division of Cardiology, Baylor University Medical Center, Dallas, Texas8Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, Texas9Texas A&M Health Science Center College of Medicine, Dallas. · Perelman School of Medicine, University of Pennsylvania, Philadelphia. · Perelman School of Medicine, University of Pennsylvania, Philadelphia11Division of Cardiology, Department of Medicine, Columbia University, New York, New York12Irving Institute for Clinical and Translational Research, Columbia University, New York, New York. ·JAMA Dermatol · Pubmed #27556410.

ABSTRACT: Importance: Psoriasis is associated with an increased risk of cardiovascular diseases. Subclinical atherosclerosis in patients with psoriasis has not been compared with other conditions associated with increased cardiovascular risk and more rigorous cardiovascular disease screening, such as type 2 diabetes. Objective: To assess the burden of asymptomatic coronary atherosclerosis measured by coronary artery calcium score in patients with moderate to severe psoriasis compared with patients with type 2 diabetes and healthy controls. Design, Setting, and Participants: Three single-center, cross-sectional studies were performed in patients recruited from specialty outpatient clinics with moderate to severe psoriasis without type 2 diabetes (recruited from November 1, 2013, through April 31, 2015), patients with type 2 diabetes without psoriasis or other inflammatory diseases (recruited from July 1, 2009, through June 20, 2011), and age- and sex-matched healthy controls without psoriasis, type 2 diabetes, or other inflammatory diseases (recruited from July 1, 2009, through June 20, 2011). Exposures: Psoriasis, type 2 diabetes, and healthy control effect on coronary artery calcium score. Main Outcomes and Measures: Coronary artery calcium measured by Agatston score. Results: A total of 387 individuals participated in the study. Mean (SD) age was 51 (7.7), 52 (8.0), and 52 (8.0) years in the psoriasis, type 2 diabetes, and healthy control cohorts, respectively. There were 64 men (49.6%) in each group, and most patients were white (119 [92.2%], 123 [95.3%], and 128 [99.2%] in the psoriasis, type 2 diabetes, and healthy control cohorts, respectively). Patients with psoriasis had low cardiovascular risk measured by the Framingham Risk Score but had a high prevalence of cardiovascular and cardiometabolic risk factors, similar to patients with type 2 diabetes. In a fully adjusted model, psoriasis was associated with coronary artery calcium (Tobit regression ratio, 0.89; P < .001) similar to the association in type 2 diabetes (Tobit regression ratio, 0.79; P = .04). Likelihood ratio testing revealed incremental value for psoriasis in a fully adjusted model (χ2 = 4.48, P = .03) in predicting coronary artery calcium. Psoriasis was independently associated with the presence of any coronary artery calcium (odds ratio, 2.35; 95% CI, 1.12-4.94) in fully adjusted models, whereas the association of coronary artery calcium with type 2 diabetes was no longer significant after adding body mass index to the model (odds ratio, 2.18; 95% CI, 0.75-6.35). Conclusions and Relevance: Patients with psoriasis have increased coronary artery calcium by mean total Agatston scores, similar to that of patients with type 2 diabetes, suggesting that patients with psoriasis harbor high rates of subclinical atherosclerosis beyond adjustment for body mass index. Major educational efforts for patients and physicians should be undertaken to reduce the burden of cardiovascular disease in patients with psoriasis.

8 Article Reporting of MABp1 for the Treatment of Psoriasis. 2015

Mansouri, Bobbak / Menter, Alan. ·Division of Dermatology, Baylor University Medical Center, Dallas, Texas. ·JAMA Dermatol · Pubmed #26465764.

ABSTRACT: -- No abstract --

9 Article Tumor Necrosis Factor-α Inhibitor Use in Psoriasis Patients With a First-degree Relative With Multiple Sclerosis. 2015

Mansouri, Bobbak / Horner, Mary E / Menter, Alan. · ·J Drugs Dermatol · Pubmed #26267733.

ABSTRACT: Tumor necrosis factor (TNF)-α inhibitors are currently the gold standard for treating moderate to severe plaque psoriasis and other immune-mediated diseases. The presence of previously existing demyelinating disease is amongst the contraindications to their use. However, controversy surrounds the use of TNF-α inhibitors in patients who are more predisposed to developing multiple sclerosis (MS), specifically first-degree relatives of MS patients. In fact, the major guidelines committees' recommendations on this issue by the American Academy of Dermatology, the British Association of Dermatologists, and the European S3-Guidelines are not consistent. The data we present suggest that the number needed to treat is at least an order of magnitude smaller than the number needed to harm across all comparisons of anti-TNF-α agents and first-degree relative relationships. Based on these data, physicians could weigh the treatment options available and work closely with neurological colleagues when prescribing anti-TNF-α therapy in this patient population rather than practicing absolute prohibition of anti-TNF-α agents in patients who have a first-degree relative with MS.

10 Article Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. 2015

Mansouri, B / Richards, L / Menter, A. ·Division of Dermatology, Baylor University Medical Center, 3900 Junius Street, Suite 125, Dallas, TX, 75204, U.S.A. · Texas A&M Health Science Center College of Medicine, Dallas, TX, U.S.A. ·Br J Dermatol · Pubmed #25495649.

ABSTRACT: Generalized pustular psoriasis (GPP) is a severe, potentially life-threatening inflammatory dermatosis, which is traditionally difficult to manage. Recent evidence suggests that interleukin (IL)-1 plays a central role in the disease pathogenesis, and thus makes the use of IL-1 inhibitors potentially effective. Two patients with severe, recalcitrant GPP were enrolled in an open-label, expanded access study to receive a new IL-1β inhibitor, gevokizumab. The two patients had a respective 79% and 65% reduction in GPP area and severity index scores at weeks 4 and 12, with some improvements in quality-of-life instruments. There were no significant adverse events related to the study medication, although one patient developed an abscess in a haematoma secondary to an injury. Both patients showed substantial initial clinical response to gevokizumab, with no significant laboratory abnormalities noted. These cases illustrate the growing need for targeted, efficacious therapies for this severe, debilitating disease. Prospective randomized control studies are required to further assess the safety and efficacy of IL-1β inhibitors for the treatment of GPP.

11 Minor Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab. 2016

Mansouri, B / Kivelevitch, D / Campa, M / Menter, A. ·Division of Dermatology, Baylor University Medical Center, Baylor Scott & White, 3900 Junius Street, Suite 145, Dallas, TX, USA. amderm@gmail.com. · Division of Dermatology, Baylor University Medical Center, Baylor Scott & White, 3900 Junius Street, Suite 145, Dallas, TX, USA. · Baylor Institute for Immunology Research, Baylor University Medical Center, Baylor Scott & White, 3900 Junius Street, Suite 145, Dallas, TX, USA. · Department of Pathology, Baylor University Medical Center, Baylor Scott & White, 3900 Junius Street, Suite 145, Dallas, TX, USA. ·Clin Exp Dermatol · Pubmed #26344848.

ABSTRACT: -- No abstract --

12 Minor Re: Complete Clinical Remission of Psoriasis 6 Months After Renal Transplantation. 2015

Mansouri, Bobbak / Kivelevitch, Dario. ·Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA; Division of Dermatology, Texas A&M College of Medicine, Scott and White Hospital, Temple, TX, USA. Electronic address: bobbak.mansouri@gmail.com. · Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA. ·Transplant Proc · Pubmed #26293100.

ABSTRACT: -- No abstract --

13 Minor Complementary data for long-term infliximab use in psoriasis. 2014

Mansouri, Bobbak / Menter, Alan. ·Division of Dermatology, Baylor University Medical Center, Dallas, Texas. · Division of Dermatology, Baylor University Medical Center, Dallas, Texas. Electronic address: amderm@gmail.com. ·J Am Acad Dermatol · Pubmed #25128111.

ABSTRACT: -- No abstract --